PD-L1 Biomarkers

Roche Gets Expanded CE Mark for Ventana PD-L1 Assay to ID NSCLC Patients for Tecentriq

Bristol Myers Squibb's Opdualag Gets EMA CHMP Recommendation for Biomarker-Selected Melanoma

Zenith Epigenetics to Explore BET Inhibitor Combinations in Multiple NCI-Sponsored Trials

FDA Investigators Share Insights on First-Line Immunotherapy Regimens in NSCLC

NICE Recommends Keytruda, Chemo Combo for Advanced TNBC, Narrows PD-L1 Expression Threshold

City of Hope, Imugene Begin Trial of Oncolytic Virus in Advanced Solid Cancers

BMS's Opdivo, Yervoy Combo Fails to Improve Overall Survival Versus Chemo in Bladder Cancer Trial

NICE Recommends AstraZeneca's Imfinzi for PD-L1-Positive NSCLC

Roche Immunotherapy Combo Misses Progression-Free Survival Endpoint in First-Line NSCLC Trial

Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors

Lunit Gets CE Mark for AI-Based PD-L1 Expression Test

EMA's CHMP Recommends Keytruda Neoadjuvant, Adjuvant Therapy in Triple-Negative Breast Cancer

BeiGene Updates Phase III Data, Biomarker Analysis for Anti-PD-1 Drug in Nasopharyngeal Cancer

BostonGene Closes $150M Series B Funding Round

Agilent Expands CE-IVD Mark for Companion Dx Tests Alongside BMS European Opdivo Approvals

EMA's CHMP Issues Positive Recommendation for Merck's Keytruda in PD-L1-Expressing Cervical Cancers

Roche, Bristol Myers Squibb Partner on Digital Pathology Algorithms, Assays for Cancer Diagnosis